Abstract: After nearly 3 years of the COVID-19 pandemic, even though a vast body of knowledge and products (including vaccines and treatments) have been developed and disseminated, the virus is still evolving and new variants arising. Consequently, thousands of lives continue to be lost. Neutralizing monoclonal antibodies (nAbs) are promising drugs that emerged to treat SARS-CoV-2. In the uncertainty of the current situation, there is the question of whether organizations should continue to invest in this technology. To help decision-making in scientifical and pharmaceutical organizations, it is of major importance to monitor the development of products and technologies. Therefore, the aim of this study is analyze the landscape of nAbs for COVID-19.
Author(s): Aline de Almeida Oliveira, Diana Praia Borges Freire, Ana Rodrigues de Andrade, Amanda de Miranda Marques, Luciana da Silva Madeira, José Procópio Moreno Senna, Ivna Alana Freitas Brasileiro da Silveira, Beatriz de Castro Fialho
Organization(s): Bio-Manguinhos/Fiocruz
Source: Journal of Pharmaceutical Innovation
Year: 2023